Sanjay Chanda - Jan 3, 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Development Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda
Stock symbol
ANTX
Transactions as of
Jan 3, 2025
Transactions value $
-$3,965
Form type
4
Date filed
1/7/2025, 08:00 PM
Previous filing
Mar 18, 2024
Next filing
Feb 28, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Sale -$3.97K -2.96K -9.02% $1.34 29.8K Jan 3, 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025.
F2 Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
F3 Includes 2,224 shares purchased on March 31, 2024 under the Issuer's Employee Stock Purchase Plan ("ESPP") and 2,322 shares purchased on September 30, 2024 under ESPP in transactions exempt from reporting under Section 16(b)3.